9.65  -0.07 (-0.72%)		10-23 16:00
Open: 9.7 High: 9.8999 Volume: 922,477		Pre. Close: 9.72 Low: 9.58 Market Cap: 943(M)

Short term
Mid term
Targets	6-month :	12.61	1-year :	13.66
Resists	First :	10.79	Second :	11.69
Pivot price	10.46
Supports	First :	9.33	Second :	7.76
MAs	MA(5) :	9.86	MA(20) :	10.34
	MA(100) :	13.91	MA(250) :	13.4
MACD	MACD :	-0.4	Signal :	-0.4
%K %D	K(14,3) :	6.3	D(3) :	12.7
RSI	RSI(14): 36.8
52-week	High :	18.89	Low :	9.33

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SPRY ] has closed above bottom band by 15.0%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	9.96 - 10.06	10.06 - 10.12
Low:	9.38 - 9.5	9.5 - 9.58
Close:	9.51 - 9.71	9.71 - 9.83

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Tue, 21 Oct 2025
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: A Biotech Player with a Promising 213% Upside Potential - DirectorsTalk Interviews

Tue, 14 Oct 2025
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Unveiling a 186.67% Potential Upside in the Biotech Arena - DirectorsTalk Interviews

Wed, 08 Oct 2025
ARS Pharmaceuticals Receives Favorable Decision from - GlobeNewswire

Sat, 04 Oct 2025
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? - Yahoo Finance

Wed, 01 Oct 2025
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly - Reuters

Mon, 29 Sep 2025
$250M Financing Deal: ARS Pharma's Needle-Free Allergy Treatment neffy Targets $2B Market Opportunity - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	99 (M)
Held by Insiders	5.209e+007 (%)
Held by Institutions	16.8 (%)
Shares Short	21,040 (K)
Shares Short P.Month	0 (K)

EPS	-5.873e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-42.8 %
Operating Margin	-303 %
Return on Assets (ttm)	-13.9 %
Return on Equity (ttm)	-23.6 %
Qtrly Rev. Growth	3 %
Gross Profit (p.s.)	51.66
Sales Per Share	1.33738e+008
EBITDA (p.s.)	1.08155e+008
Qtrly Earnings Growth	-0.5 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-53 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	4.15

Dividend	0
Forward Dividend	2.169e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.